Economic Burden of Inflammatory Bowel Disease in Shiraz, Iran

Leila Rahmati ¹ , Alireza Mooghali ², Seyed Mohammad Hosein Kamani ², Fatemeh Zare ³, Hassan Askari ¹ , Ali Reza Safarpour ¹ *

Cited by CrossRef: 2

1- Karami H, Ghanbarnejad A, Nowrouzpour M, Mouseli A, Taheri Kondar R, Shirvani Shiri M, Ebadi Fard Azar F. Cost-of-illness analysis of ulcerative colitis patients treated with biological therapy: a prospective observational study in Iran. BMC Health Serv Res. 2025;25(1) [Crossref]

2- Chen X, Xiang X, Xia W, Li X, Wang S, Ye S, Tian L, Zhao L, Ai F, Shen Z, Nie K, Deng M, Wang X. Evolving Trends and Burden of Inflammatory Bowel Disease in Asia, 1990–2019: A Comprehensive Analysis Based on the Global Burden of Disease Study. J Epidemiol Glob Health. 2023;13(4):725 [Crossref]

3- Bakhtiari Z, Mahdavi R, Masnadi Shirazi K, Nikniaz Z. Association between dietary inflammatory index and disease activity in patients with ulcerative colitis. Sci Rep. 2024;14(1) [Crossref]

Submit Your Paper Notification Instructions for Authors Aims and Scope Editorial policies Editorial Board AIM old site Archive

About Us

A Monthly Peer-Reviewed Medical Journal Published by the Academy of Medical Sciences of the I.R. Iran; Indexed in PubMed/MEDLINE, ISI Web of Science, EMBASE, SCOPUS, CINHAL, PASCAL, CSA, SID, ISSN: Print 1029-2977, Online 1735-3947.The impact factor of Archives of Iranian Medicine according to Journal Citation Reports® (JCR®) 2016 is 1.20.